Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Sanofi to pay $19.8 million over claims of drug overcharges: U.S.
Sanofi SA (SASY.
Astellas to buy GPCR specialist Ogeda for €500M upfront
Astellas has struck a deal to buy Ogeda for €500 million ($534 million) upfront.
Hepatitis B, C may raise risk of Parkinson's disease
London.
Mylan says EpiPen manufacturing partner to expand device recall
Generic drugmaker Mylan NV said on Friday that its manufacturing partner for EpiPen devices had expanded a recall of the life-saving allergy shot in the United States and other markets.
Actelion acquisition close to completion, says J&J
Updating on its proposed acquisition of Swiss biotech firm Actelion (SIX.
Espero Pharmaceuticals and Armetheon to Merge and Create a Premier Cardiovascular Focused Biopharmaceutical Company
ACKSONVILLE, Fla.
Heroin-like fish venom could help in development of new painkillers
Researchers have discovered a fish venom that contains opioid properties, which could help in the development of new pain-killing drugs.
Scientists discover mechanism that causes cancer cells to self-destruct
Many cancer patients struggle with the adverse effects of chemotherapy, still the most prescribed cancer treatment.
Vertex to shutter Canada site, focus in on 3 hubs in R&D shuffle
After posting a disappointing forecast for 2017, Vertex is consolidating its R&D operations, according to a securities filing.
Post-disastrous Valeant investment, soul-searching Ackman reflects on lessons learned
One-time Valeant enthusiast and hedge fund manager Bill Ackman has already lamented his huge bet on the now-imploded drugmaker as “one very big mistake.
FDA, Mylan silence on generic Advair may be good news for GSK
A deadline for U.
Astellas sells 16 products to LTL Pharma for $181 million
Astellas Pharma (TSE.
547
548
549
550
551
552
553
554
555
